Literature DB >> 28150131

Inflammatory Bowel Disease-Unclassified in Children: Diagnosis and Pharmacological Management.

Giulia D'Arcangelo1, Marina Aloi2.   

Abstract

Inflammatory bowel diseases are chronic disorders of the gastrointestinal tract that include Crohn's disease (CD), ulcerative colitis (UC) and inflammatory bowel disease-unclassified (IBDU). The latter defines a subgroup of patients with clinical and endoscopic evidence of chronic colitis, without specific features of either CD or UC. These patients will possibly be re-classified as having UC or CD during the follow-up, although a significant percentage of them will keep the diagnosis of IBDU. IBDU is the rarest subtype of IBD, both in children and in adults, although it is twice as common among the pediatric population, especially in the younger ages. The diagnosis can only be made after a comprehensive diagnostic work-up, combining clinical history, physical and laboratory examination, upper and lower gastrointestinal endoscopy, with histology and imaging of the small bowel. The therapeutic strategy is borrowed from that of UC and CD, although recent data suggest that IBDU has a lower therapeutic burden with a generally mild disease course and a good response to mesalamine. Since there are only few published data on pediatric IBDU, and no guidelines on its management are available, this review aims at summarizing the most recent evidence for the diagnostic work-up with a specific focus on medical and surgical options in the treatment of IBDU.

Entities:  

Mesh:

Year:  2017        PMID: 28150131     DOI: 10.1007/s40272-017-0213-9

Source DB:  PubMed          Journal:  Paediatr Drugs        ISSN: 1174-5878            Impact factor:   3.022


  44 in total

1.  Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology.

Authors:  Mark S Silverberg; Jack Satsangi; Tariq Ahmad; Ian D R Arnott; Charles N Bernstein; Steven R Brant; Renzo Caprilli; Jean-Frédéric Colombel; Christoph Gasche; Karel Geboes; Derek P Jewell; Amir Karban; Edward V Loftus; A Salvador Peña; Robert H Riddell; David B Sachar; Stefan Schreiber; A Hillary Steinhart; Stephan R Targan; Severine Vermeire; B F Warren
Journal:  Can J Gastroenterol       Date:  2005-09       Impact factor: 3.522

2.  Assessment of the validity of a multigene analysis in the diagnostics of inflammatory bowel disease.

Authors:  J T Bjerrum; C Nyberg; J Olsen; O H Nielsen
Journal:  J Intern Med       Date:  2013-11-21       Impact factor: 8.989

3.  Pediatric IBD-unclassified Is Less Common than Previously Reported; Results of an 8-Year Audit of the EUROKIDS Registry.

Authors:  Dwight A Winter; Katarzyna Karolewska-Bochenek; Izabella Lazowska-Przeorek; Paolo Lionetti; M Luisa Mearin; Sonny K Chong; Eleftheria Roma-Giannikou; Jan Maly; Kaija-Leena Kolho; Ron Shaoul; Annamaria Staiano; Gerard M Damen; Tim de Meij; Daniëlle Hendriks; Elvira K George; Dan Turner; Johanna C Escher
Journal:  Inflamm Bowel Dis       Date:  2015-09       Impact factor: 5.325

4.  Fate of the pouch in 151 pediatric patients after ileal pouch anal anastomosis.

Authors:  Frederick Alexander; Samra Sarigol; John DiFiore; Anthony Stallion; Kathy Cotman; Holly Clark; Barb Lydzinski; Victor Fazio
Journal:  J Pediatr Surg       Date:  2003-01       Impact factor: 2.545

5.  Children with early-onset inflammatory bowel disease (IBD): analysis of a pediatric IBD consortium registry.

Authors:  Melvin B Heyman; Barbara S Kirschner; Benjamin D Gold; George Ferry; Robert Baldassano; Stanley A Cohen; Harland S Winter; Patricia Fain; Chris King; Terry Smith; Hashem B El-Serag
Journal:  J Pediatr       Date:  2005-01       Impact factor: 4.406

6.  Infliximab in the treatment of medically refractory indeterminate colitis.

Authors:  K A Papadakis; L Treyzon; M T Abreu; P R Fleshner; S R Targan; E A Vasiliauskas
Journal:  Aliment Pharmacol Ther       Date:  2003-10-01       Impact factor: 8.171

7.  Infliximab for inflammatory bowel disease in Denmark 1999-2005: clinical outcome and follow-up evaluation of malignancy and mortality.

Authors:  Sarah Caspersen; Margarita Elkjaer; Lene Riis; Natalia Pedersen; Christian Mortensen; Tine Jess; Pernille Sarto; Tanja S Hansen; Vibeke Wewer; Flemming Bendtsen; Flemming Moesgaard; Pia Munkholm
Journal:  Clin Gastroenterol Hepatol       Date:  2008-10-09       Impact factor: 11.382

8.  Multigene analysis can discriminate between ulcerative colitis, Crohn's disease, and irritable bowel syndrome.

Authors:  Petra von Stein; Robert Lofberg; Nikolai V Kuznetsov; Alexander W Gielen; Jan-Olov Persson; Rolf Sundberg; Karin Hellstrom; Anders Eriksson; Ragnar Befrits; Ake Ost; Oliver D von Stein
Journal:  Gastroenterology       Date:  2008-03-02       Impact factor: 22.682

9.  Detection of antisynthetic mannoside antibodies (ASigmaMA) reveals heterogeneity in the ASCA response of Crohn's disease patients and contributes to differential diagnosis, stratification, and prediction.

Authors:  Peggy Vandewalle-El Khoury; Jean-Frederic Colombel; Sofie Joossens; Annie Standaert-Vitse; Mayeul Collot; Jonas Halfvarson; Ali Ayadi; Carol J Landers; Severine Vermeire; Paul Rutgeerts; Stephan R Targan; Mathias Chamaillard; Jean-Maurice Mallet; Boualem Sendid; Daniel Poulain
Journal:  Am J Gastroenterol       Date:  2007-11-28       Impact factor: 10.864

10.  Inflammatory bowel disease in children 5 years of age and younger.

Authors:  Petar Mamula; Grzegorz W Telega; Jonathan E Markowitz; Kurt A Brown; Pierre A Russo; David A Piccoli; Robert N Baldassano
Journal:  Am J Gastroenterol       Date:  2002-08       Impact factor: 10.864

View more
  2 in total

Review 1.  The Therapeutic Role of Short-Chain Fatty Acids Mediated Very Low-Calorie Ketogenic Diet-Gut Microbiota Relationships in Paediatric Inflammatory Bowel Diseases.

Authors:  Naser A Alsharairi
Journal:  Nutrients       Date:  2022-10-03       Impact factor: 6.706

2.  Exclusive enteral nutrition protects against inflammatory bowel disease by inhibiting NF‑κB activation through regulation of the p38/MSK1 pathway.

Authors:  Ting Yu; Qian Yu; Xiaotian Chen; Lixing Zhou; Yuming Wang; Chenggong Yu
Journal:  Int J Mol Med       Date:  2018-06-04       Impact factor: 4.101

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.